RECOMMENDATIONS FOR MONITORING LITHIUM-THERAPY

被引:5
作者
SALEM, RB
机构
[1] SUNLAND CTR,CLIN PHARM SERV,GAINESVILLE,FL
[2] UNIV FLORIDA,COLL PHARM,DEPT PHARM PRACTICE,GAINESVILLE,FL 32611
来源
DRUG INTELLIGENCE & CLINICAL PHARMACY | 1983年 / 17卷 / 05期
关键词
D O I
10.1177/106002808301700505
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:346 / 350
页数:5
相关论文
共 76 条
[1]  
ALBRECHT JW, 1980, HDB LITHIUM THERAPY, P323
[2]  
ALDOROTY N, 1980, AM J PSYCHIAT, V137, P870
[3]  
BALDESSARINI RJ, 1970, ARCH GEN PSYCHIAT, V22, P72
[4]   CUTANEOUS CONDITIONS OBSERVED IN PATIENTS DURING TREATMENT WITH LITHIUM [J].
CALLAWAY, CL ;
HENDRIE, HC ;
LUBY, ED .
AMERICAN JOURNAL OF PSYCHIATRY, 1968, 124 (08) :1124-&
[5]  
CARMAN JS, 1979, AM J PSYCHIAT, V136, P1035
[6]  
CARTER TN, 1972, PSYCHOSOMATICS, V13, P325
[7]  
CERVISKINNER SJ, 1977, WESTERN J MED, V127, P527
[8]  
CHO JT, 1979, AM J PSYCHIAT, V136, P115
[9]  
CHRISTENSSON TAT, 1976, LANCET, V2, P144
[10]   DEVELOPMENT OF PRIMARY HYPERPARATHYROIDISM DURING LITHIUM-THERAPY - LONGITUDINAL-STUDY [J].
CHRISTIANSEN, C ;
BAASTRUP, PC ;
TRANSBOL, I .
NEUROPSYCHOBIOLOGY, 1980, 6 (05) :280-283